Business of Optometry News

Investing is challenging, and the task has become increasingly difficult as our access to information has evolved during the past decade.

  The FDA approved an expanded label for Iluvien, which is now indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye, according to a press release from ANI Pharmaceuticals.

Investing in bonds may seem boring and not sexy like buying individual stocks, but bonds help provide diversification and stability to one’s portfolio.

  The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

It’s been a busy first quarter here at Healio Community.

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription Drug User Fee Act date of Oct. 23, according to a press release from Sydnexis.

  The FDA approved Encelto, an encapsulated cell therapy, for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.

Physicians typically have tax reduction and long-term wealth accumulation at the top of their financial objectives.

In this Healio Video Perspective from SECO 2025, Kristen Brotherson, general manager of U.S. vision care at Alcon, outlined the company’s latest eye care innovations being premiered at the meeting.